Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability.

  title={Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability.},
  author={Ingo Vernaleken and Majken Klomp and Olaf Moeller and Mardjan Raptis and Arne Nagels and Frank R{\"o}sch and Wolfgang M. Schaefer and Paul Cumming and Gerhard Gr{\"u}nder},
  journal={The international journal of neuropsychopharmacology},
  volume={16 4},
Previous positron emission tomography (PET) studies employing competition paradigms have shown either no change or substantial declines in striatal [(11)C]-raclopride binding after challenge with psychotogenic doses of the N-methyl-D-aspartate antagonist ketamine. We sought to probe the relationship between the severity of ketamine-induced psychotic symptoms and altered dopamine D(2/3) receptor availability throughout brain using the high affinity ligand [(18)F]-fallypride (FP). PET recordings… 

Figures and Tables from this paper

The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders

Evidence is provided that acute ketamine administration leads to dopamine release in the rodent brain and the implications for understanding psychiatric disorders, in particular substance abuse, schizophrenia, and the potential antidepressant properties of ketamine, and comparisons with stimulants and other NMDA antagonists.

Do the dissociative side effects of ketamine mediate its antidepressant effects?

Ketamine abuse potential and use disorder

Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum

The data show, for the first time in humans, an interaction between dopamine, glutamate, and the neural signature of response inhibition in the striatum, which stresses the importance of the dopamine–glutamate interaction for behavior and may facilitate the understanding of psychiatric disorders characterized by impaired response inhibition.

Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes

Ass associations indicate a role for gene variants related to glutamate signaling and antipsychotic response with more broad association patterns indicating the potential importance of genes involved in neuronal development.

Glutamate and dopamine in schizophrenia: An update for the 21st century

This review provides an update on the latest findings on dopamine and glutamate abnormalities in schizophrenia, focusing on in vivo neuroimaging studies in patients and clinical high-risk groups, and considers their implications for understanding the biology and treatment of schizophrenia.

Neuropsychological Correlates of Transcription Factor AP-2Beta, and Its Interaction with COMT and MAOA in Healthy Females

Interactions of transcription factors AP-2β, COMT, and MAOA polymorphisms suggest higher leverage effects of transcription factor AP-1β in subjects with high dopamine availability and more influence on cognition than the MAOA and COMT polymorphisms.

Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression

Observations indicate ketamine use requires close safety and tolerability monitoring with regards to psychomimetic and dissociative symptoms in TRD-BP and careful management for MDD patients.



NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans

These data fail to demonstrate an effect of ketamine on [11C]raclopride BP and are consistent with microdialysis studies in rodents and nonhuman primates which reported only small effects of acute NMDA receptor blockade on extracellular striatal DA concentration.

Ketamine does not decrease striatal dopamine D2 receptor binding in man

This controlled study indicates that ketamine does not decrease striatal [11C]raclopride binding, andstriatal dopamine release is of minor importance in the psychosis-like effects of ketamine.

Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine

Present results are consistent with stimulation of DDC activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine, and suggest that this response is an important mechanism underlying the anti‐parkinsonian properties of amanadine.

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach

Ketamine‐induced changes in 11C‐raclopride‐specific binding were significantly correlated with induction of schizophrenia‐like symptoms and the implications of this brain imaging method for studies of schizophrenia and the mechanism of action of antipsychotic drugs are discussed.

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

The hypothesis that lamotrigine, a drug reported to inhibit glutamate release, will reduce the neuropsychiatric effects of ketamine in humans is tested and it is suggested that glutamate release-inhibiting drugs may reduce the hyperglutamatergic consequences of NMDA receptor dysfunction implicated in the pathophysiologic processes of neuro psychological illnesses such as schizophrenia.

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

These data indicate that N-methyl-D-aspartate antagonists produce a broad range of symptoms, behaviors, and cognitive deficits that resemble aspects of endogenous psychoses, particularly schizophrenia and dissociative states.

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.

Its dissociation from those receptors is very slow, such that in patients with serum aripiprazole concentrations in the range typical for clinical practice, D(2)/D(3) receptors must remain nearly saturated for as long as 1 week after the last dose.